Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis | Zendy

William J. Sandborn | Zendy; Chinyu Su | Zendy; Bruce E. Sands | Zendy; Geert R. DʼHaens | Zendy; Séverine Vermeire | Zendy; Stefan Schreiber | Zendy; Silvio Danese | Zendy; Brian G. Feagan | Zendy; Walter Reinisch | Zendy; Wojciech Niezychowski | Zendy; Gary S. Friedman | Zendy; Nervin Lawendy | Zendy; Dahong Yu | Zendy; Deborah A. Woodworth | Zendy; Arnab Mukherjee | Zendy; Haiying Zhang | Zendy; Paul J. Healey | Zendy; Julián Panés | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

Author(s) -

William J. Sandborn,

Chinyu Su,

Bruce E. Sands,

Geert R. DʼHaens,

Séverine Vermeire,

Stefan Schreiber,

Silvio Danese,

Brian G. Feagan,

Walter Reinisch,

Wojciech Niezychowski,

Gary S. Friedman,

Nervin Lawendy,

Dahong Yu,

Deborah A. Woodworth,

Arnab Mukherjee,

Haiying Zhang,

Paul J. Healey,

Julián Panés

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1606910

Subject(s) - tofacitinib , ulcerative colitis , medicine , janus kinase inhibitor , maintenance therapy , induction therapy , janus kinase , colitis , gastroenterology , chemotherapy , receptor , disease , rheumatoid arthritis

Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the efficacy of tofacitinib as induction and maintenance therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research